Open AccessHES 130/0.4 (Voluven®) or human albumin in children younger than 2 yr undergoing non-cardiac surgery. A prospective, randomized, open label, multicentre trial
Author(s) -
Thomas Standl,
H. Lochbuehler,
C. Galli,
Alexander Reich,
G. Dietrich,
H Hagemann
Publication year - 2008
Publication title -
european journal of anaesthesiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.445
H-Index - 76
eISSN - 1365-2346
pISSN - 0265-0215
DOI - 10.1017/s0265021508003888
Subject(s) - hydroxyethyl starch , medicine , perioperative , albumin , anesthesia , hetastarch , serum albumin , randomized controlled trial , surgery , prospective cohort study
For perioperative volume therapy in infants and young children, human albumin has frequently been the colloid of choice. Recently, HES 130/0.4 (6% hydroxyethyl starch, Voluven; Fresenius Kabi, Bad Homburg, Germany) was developed, which demonstrated improved pharmacokinetics and a favourable safety profile in adults compared with hydroxyethyl starch products with a less rapid metabolization.